RxDoctor Payments Data

Frank Anderson, MD

Gastroenterology · Santa Rosa, CANPI 1487691192

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 47.2% of the total. Reporting peaked in 2022 at $545 and has fallen 94.6% since, to $29 in 2025. That places this record below the midpoint for gastroenterology clinicians in CA, where the typical reported total is $1,790.

$1,133in general payments, 2019–2025

Across 15 payments — averaging $75.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$535
  • Boston Scientific$140
  • Sanofi$126
  • Phathom Pharmaceuticals, Inc.$108
  • Takeda Pharmaceuticals U.S.A., Inc.$91
  • Johnson & Johnson$55
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$1,10397%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,133 in reported general payments places this provider in the 40th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California →

Medicare billing

Part B allowed, 2024
$118,991
Medicare patients
414
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide37$24,916
CreonLipase/Protease/Amylase14$20,238
Budesonide DrBudesonide36$6,202
Pantoprazole Sodium359$4,901
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg190$4,277
Tenofovir Disoproxil Fumarate11$3,588
Mesalamine16$3,136
Famotidine95$2,596
Omeprazole192$2,531
Sucralfate44$2,115
Budesonide EcBudesonide18$1,379
CholestyramineCholestyramine (With Sugar)25$1,096
Prednisone12$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$535$45,15451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Santa Rosa

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →